Free Trial

This company has been marked as potentially delisted and may not be actively trading.

GX Acquisition (GXGX) Competitors

GXGX vs. MBX, AVTE, NLTX, CYBN, BIOA, VIRI, WHWK, ATNM, PYRGF, and OSTX

Should you be buying GX Acquisition stock or one of its competitors? The main competitors of GX Acquisition include MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), Cybin (CYBN), BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), Actinium Pharmaceuticals (ATNM), PyroGenesis Canada (PYRGF), and OS Therapies (OSTX).

GX Acquisition vs. Its Competitors

GX Acquisition (NASDAQ:GXGX) and MBX Biosciences (NYSE:MBX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GX AcquisitionN/AN/A-$49.26MN/AN/A
MBX BiosciencesN/AN/AN/AN/AN/A

MBX Biosciences has a consensus target price of $37.57, suggesting a potential upside of 173.25%. Given MBX Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe MBX Biosciences is more favorable than GX Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GX Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
MBX Biosciences
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

61.7% of GX Acquisition shares are owned by institutional investors. 52.2% of MBX Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

MBX Biosciences' return on equity of 0.00% beat GX Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
GX AcquisitionN/A -985.20% -6.02%
MBX Biosciences N/A N/A N/A

In the previous week, MBX Biosciences had 1 more articles in the media than GX Acquisition. MarketBeat recorded 1 mentions for MBX Biosciences and 0 mentions for GX Acquisition. MBX Biosciences' average media sentiment score of 1.16 beat GX Acquisition's score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
GX Acquisition Neutral
MBX Biosciences Positive

Summary

MBX Biosciences beats GX Acquisition on 8 of the 9 factors compared between the two stocks.

Get GX Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for GXGX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GXGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GXGX vs. The Competition

MetricGX AcquisitionPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$112.12M$771.04M$5.49B$9.52B
Dividend YieldN/A4.84%4.73%4.09%
P/E RatioN/A1.3428.7523.81
Price / SalesN/A25.68372.2066.02
Price / CashN/A19.5635.4557.96
Price / Book22.296.778.275.55
Net Income-$49.26M-$3.67M$3.25B$259.20M

GX Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GXGX
GX Acquisition
N/A$3.12
-4.9%
N/A+4.1%$112.12MN/A0.00N/A
MBX
MBX Biosciences
2.6586 of 5 stars
$13.68
+16.9%
$37.57
+174.6%
N/A$457.24MN/A0.0036Positive News
Gap Down
High Trading Volume
AVTE
Aerovate Therapeutics
N/A$8.98
+3.3%
N/A-88.5%$260.29MN/A-3.0020High Trading Volume
NLTX
Neoleukin Therapeutics
N/A$22.34
-1.2%
N/A-46.3%$209.95MN/A-7.1890High Trading Volume
CYBN
Cybin
2.5922 of 5 stars
$7.76
+0.4%
$85.00
+995.4%
N/A$178.67MN/A-1.7750
BIOA
BioAge Labs
N/A$4.85
+1.9%
N/AN/A$170.65MN/A0.00N/APositive News
VIRI
Virios Therapeutics
N/A$4.69
-2.5%
$5.00
+6.6%
+2,247.1%$90.32MN/A-17.375Upcoming Earnings
WHWK
Whitehawk Therapeutics
N/A$2.01
+7.5%
N/AN/A$88.09M$27.78M12.5640Gap Up
ATNM
Actinium Pharmaceuticals
1.9786 of 5 stars
$1.87
+2.7%
$4.00
+113.9%
-75.6%$58.34MN/A-1.3530News Coverage
Positive News
PYRGF
PyroGenesis Canada
0.3783 of 5 stars
$0.30
-5.5%
N/A-53.5%$56.19M$9.14M-5.0090News Coverage
Gap Up
High Trading Volume
OSTX
OS Therapies
2.1009 of 5 stars
$1.83
+0.5%
$18.00
+883.6%
N/A$51.42MN/A-2.13N/A

Related Companies and Tools


This page (NASDAQ:GXGX) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners